Sahakian Nicolas, Castinetti Frédéric, Brue Thierry, Cuny Thomas
Department of Endocrinology, Hôpital de la Conception, Centre de Référence des Maladies Rares Hypophysaires HYPO, INSERM, U1251, Marseille Medical Genetics, France and AP-HM, Aix-Marseille Université, 13005 Marseille, France.
J Clin Med. 2022 Feb 12;11(4):955. doi: 10.3390/jcm11040955.
Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option. Nonetheless, the role played by medical therapies for the management of such tumors, before or after surgery, has evolved considerably, due in part to the recent development of well-tolerated and highly efficient molecules. In this review, our aim was to present a state-of-the-art of the current medical therapies used in the field of PT and the benefits and caveats for each of them, and further specify their positioning in the therapeutic algorithm of each phenotype. Finally, we discuss the future of PT medical therapies, based on the most recent studies published in this field.
垂体瘤（PT）在大多数情况下是良性肿瘤，除分泌催乳素的垂体瘤外，手术治疗仍是其一线治疗选择。然而，药物治疗在这类肿瘤手术前后管理中所起的作用已发生了很大变化，部分原因是近年来出现了耐受性良好且高效的分子。在本综述中，我们的目的是介绍垂体瘤领域当前使用的药物治疗的最新情况以及每种治疗的益处和注意事项，并进一步明确它们在每种表型治疗算法中的定位。最后，我们根据该领域发表的最新研究讨论垂体瘤药物治疗的未来。
